A detailed history of Tower Research Capital LLC (Trc) transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,859 shares of GLUE stock, worth $15,541. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,859
Previous 13,452 86.18%
Holding current value
$15,541
Previous $50,000 82.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.59 - $6.97 $41,618 - $80,803
-11,593 Reduced 86.18%
1,859 $9,000
Q2 2024

Aug 13, 2024

BUY
$3.38 - $7.86 $43,703 - $101,629
12,930 Added 2477.01%
13,452 $50,000
Q1 2024

May 15, 2024

SELL
$4.26 - $8.46 $30,987 - $61,538
-7,274 Reduced 93.3%
522 $3,000
Q4 2023

Feb 13, 2024

SELL
$2.5 - $5.93 $23,417 - $55,546
-9,367 Reduced 54.58%
7,796 $44,000
Q3 2023

Nov 14, 2023

BUY
$4.78 - $7.22 $74,066 - $111,873
15,495 Added 928.96%
17,163 $82,000
Q2 2023

Aug 14, 2023

SELL
$4.53 - $8.4 $3,062 - $5,678
-676 Reduced 28.84%
1,668 $11,000
Q1 2023

May 09, 2023

BUY
$5.95 - $8.21 $5,283 - $7,290
888 Added 60.99%
2,344 $18,000
Q4 2022

Feb 10, 2023

SELL
$6.71 - $9.72 $89,672 - $129,898
-13,364 Reduced 90.18%
1,456 $11,000
Q3 2022

Nov 10, 2022

BUY
$7.17 - $12.16 $54,312 - $92,112
7,575 Added 104.55%
14,820 $121,000
Q2 2022

Aug 15, 2022

BUY
$6.15 - $14.99 $28,474 - $69,403
4,630 Added 177.06%
7,245 $70,000
Q1 2022

May 12, 2022

BUY
$10.36 - $20.41 $22,346 - $44,024
2,157 Added 470.96%
2,615 $37,000
Q4 2021

Feb 14, 2022

SELL
$16.28 - $27.15 $15,091 - $25,168
-927 Reduced 66.93%
458 $9,000
Q3 2021

Nov 15, 2021

BUY
$18.59 - $42.21 $18,311 - $41,576
985 Added 246.25%
1,385 $31,000
Q2 2021

Aug 16, 2021

BUY
$18.86 - $22.7 $7,544 - $9,080
400 New
400 $9,000

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $391M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.